In October 2019, the United States Food and Drug Administration (FDA) approved MT1 under the brand name Scenesse for increasing sunlight tolerance and alleviating pain from ultraviolet (UV) light exposure in patients with erythropoietic protoporphyria (EPP) [4]
There is not yet enough comparative human data to answer this definitively
Year-3 adherence and persistence research abstract Learn more about the methodology of Primes research study, GLP-1 Therapy to Treat Obesity Among Members Without Diabetes: Three-Year Persistence and Year-Over-Year Persistence Rate Change. Historical Adherence and persistence data Primes real-world, integrated data revealed further insights at Year 2, including that just 1 in 7 people remain on GLP-1 drugs for weight loss
Oral glutathione supplements have historically shown poor bioavailability, meaning much of the ingested glutathione is broken down in the digestive system before reaching the bloodstream
Can compounded GLP-1 medications affect medication reconciliation
But labs are testing the blend to monitor recovery markers, as well as to compare it to typical BPC-157 + TB-500 regimens